What happens when you take smoking with olanzapine?
Tobacco smoke contains polycyclic aromatic hydrocarbons (PAHs) that strongly induce the liver enzyme CYP1A2. CYP1A2 is the main enzyme responsible for breaking olanzapine down in the body. When smoking induces this enzyme, olanzapine is cleared from the bloodstream more quickly, and plasma levels drop.
The size of this effect is substantial. Population pharmacokinetic studies show that olanzapine clearance is roughly 37-48% higher in smokers than in non-smokers. A 2014 BMJ Open meta-analysis pooling 1,094 patients concluded that olanzapine doses should be reduced by about 30% in non-smokers compared with smokers to achieve equivalent plasma concentrations. Other work using CYP1A2 phenotyping has shown up to sixfold higher CYP1A2 activity in heavy smokers.
The induction is driven by smoke, not by nicotine. That distinction matters: nicotine patches, gum, lozenges, and most e-cigarettes do not raise CYP1A2 activity, so they do not interact with olanzapine in this way. Cannabis smoking, however, contains the same combustion-derived PAHs and can produce a similar induction effect.
The induction is reversible. When a patient stops smoking, CYP1A2 activity returns toward baseline within a few days, and olanzapine plasma levels can rise sharply over the first 1-2 weeks of abstinence.
Why is this important?
Olanzapine has a meaningful side-effect profile that becomes harder to tolerate at higher plasma levels. Common dose-related side effects include sedation, weight gain, increased appetite, dizziness on standing, dry mouth, constipation, and metabolic effects like elevated blood sugar and triglycerides. Less commonly, very high levels can contribute to QT prolongation, seizures, or neuroleptic malignant syndrome.
Among the many factors that influence olanzapine concentrations - age, sex, ancestry, co-medications, and CYP1A2 genotype - smoking has been identified as the single most important. A patient who has been well controlled on a stable dose for years can develop new sedation, weight gain, and metabolic side effects in the weeks after quitting smoking, even though nothing else has changed.
The opposite scenario also matters. A patient discharged from a smoke-free inpatient unit who resumes smoking at home may notice a return of psychotic symptoms because their plasma olanzapine levels are falling. Without recognizing the smoking link, clinicians may misinterpret this as treatment failure and escalate the dose unnecessarily.
What should you do?
Tell your psychiatrist how much you currently smoke and let them know before any planned change in smoking status. This includes serious quit attempts, hospital admissions to smoke-free facilities, surgery, residential treatment, and incarceration.
If you are stopping smoking, expect your prescriber to consider a dose reduction of roughly 30% over the first 1-2 weeks. Watch for new sedation, oversleeping, dizziness, increased appetite or weight gain, and let your team know. If you have been told to quit but are also worried about psychiatric stability, nicotine replacement therapy (patches, gum, lozenges, inhalers, sprays) and varenicline do not change CYP1A2 activity and can be used safely.
If you are resuming smoking after a period of abstinence, do not assume your previous lower dose will still work; talk to your prescriber rather than increasing the dose yourself. Plasma level monitoring is not routine for olanzapine the way it is for clozapine, so clinical observation matters even more.
Which specific products are affected?
The interaction applies to all forms and brands of olanzapine, including Zyprexa, Zyprexa Zydis (orally disintegrating tablets), generic olanzapine tablets, the long-acting Zyprexa Relprevv injection, and combination products such as olanzapine/fluoxetine (Symbyax) and olanzapine/samidorphan (Lybalvi).
The substances that drive the interaction are combustion products: cigarettes, cigars, pipes, hookah, and cannabis smoke. Smokeless tobacco, nicotine pouches, nicotine patches, nicotine gum, and most e-cigarettes do not contain meaningful amounts of polycyclic aromatic hydrocarbons and are not expected to alter olanzapine metabolism. Data suggest as few as 7-12 cigarettes per day is enough to produce near-maximal CYP1A2 induction, so even light smokers can be affected.
The bottom line
Smoking lowers olanzapine blood levels by inducing CYP1A2 metabolism, and quitting raises them by roughly 30% over 1-2 weeks. Tell your prescriber about any change in smoking habits, expect a dose adjustment downward when you quit, and use nicotine replacement freely - it does not cause this interaction because nicotine itself is not the culprit. The combustion products are.